Table 4.
Challenge | Solution |
---|---|
Nucleases mediated degradation | Chemical modification |
Rapid renal clearance (short half-lives) | Increasing the weight of aptamer by conjugating cholesterol or PEG |
Cost of production | Decrease the usage of aptamer |
Toxicity (nonspecific immune activation and polyanionic effects) | Cautious modification |